Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Net Income (2016 - 2025)

Perspective Therapeutics' Net Income history spans 16 years, with the latest figure at $514000.0 for Q2 2025.

  • For Q2 2025, Net Income rose 204.9% year-over-year to $514000.0; the TTM value through Sep 2025 reached $514000.0, up 108.38%, while the annual FY2024 figure was -$949000.0, 89.52% up from the prior year.
  • Net Income for Q2 2025 was $514000.0 at Perspective Therapeutics, up from -$490000.0 in the prior quarter.
  • Across five years, Net Income topped out at $514000.0 in Q2 2025 and bottomed at -$5.2 million in Q4 2023.
  • The 5-year median for Net Income is -$1.3 million (2022), against an average of -$1.6 million.
  • The largest annual shift saw Net Income tumbled 681.82% in 2022 before it soared 204.9% in 2025.
  • A 5-year view of Net Income shows it stood at $330000.0 in 2021, then crashed by 681.82% to -$1.9 million in 2022, then plummeted by 169.95% to -$5.2 million in 2023, then surged by 90.55% to -$490000.0 in 2024, then skyrocketed by 204.9% to $514000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Net Income are $514000.0 (Q2 2025), -$490000.0 (Q2 2024), and -$459000.0 (Q1 2024).